Table 1 Characteristic of included studies in meta-analysis

Woo et al. 1999 [32]

China

Crossover, R, PC, DB

Healthy Adults

M/F: 17

17

17

8

54 ± 10

54 ± 10

NR

NR

10

Placebo

Bellamy et al. 1999 [43]

United Kingdom

Crossover, R, PC, DB

hyperhomocysteinaemic subjects

M/F: 18

18

18

6

NR

NR

NR

NR

5

Placebo

Title et al. 2000 [30]

United Kingdom

Paralell, R, PC, DB

Patients With Predialysis Renal Failure

M/F: 100

50

50

12

61 ± 7

62 ± 7

28.2 ± 3.2

27.5 ± 2.7

5

Placebo

Thambyrajah et al. 2000 [33]

Canada

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 50

25

25

16

57.2 ± 9.8

60.6 ± 8.6

NR

NR

5

Placebo

Doshi et al. 2001 [44]

United Kingdom

Crossover, R, PC, DB

Coronary Artery Disease

M/F: 50

50

50

6

57 ± 8

57 ± 8

28.5 ± 4.4

28.5 ± 4.4

5

Placebo

Thambyrajah et al. 2001 [34]

United Kingdom

Crossover, R, PC, DB

Healthy Adults

M/F: 126

126

126

16

39 ± 12

39 ± 12

NR

NR

0.4

Placebo

Pullin et al. 2001 [45]

United Kingdom

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 86

43

43

12

63 ± 4.9

63.4 ± 4.3

28.6 ± 2.8

27.2 ± 2.1

5

Placebo

Doshi et al. 2002 [46]

United Kingdom

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 33

16

17

6

55 ± 7

56 ± 7

NR

NR

5

placebo

Doshi et al. 2003 [47]

United Kingdom

Paralell, R, PC, DB

Coronary Heart Disease

M/F: 83

33

50

6

56 ± 7

57 ± 8

28.9 ± 5.99

28.5 ± 4.4

5

Placebo

Doshi et al. 2004 [48]

Netherlands

Paralell, R, PC, DB

patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia

M/F: 41

23

18

24

63.7 ± 8.6

66.1 ± 8.5

29.3 ± 3.9

28.8 ± 3.4

5

Placebo

Woodman et al. 2004 [35]

United Kingdom

Crossover, R, PC, DB

coronary heart disease

M/F: 50

50

50

24

57 ± 8

57 ± 8

28.5 ± 4.4

28.5 ± 4.4

5

Placebo

Lekakis et al. 2004 [29]

Greece

Paralell, R, PC, DB

patients with hypercholesterolaemia receiving statins

M/F: 34

17

17

4

55.7 ± 8.3

57.3 ± 8.8

NR

NR

5

Placebo

Spoelstra-de Man et al. 2004 [36]

Australia

Crossover, R, PC, DB

healthy hyperhomocysteinaemic subjects (High tHcy)

M/F: 26

26

26

8

49 ± 10

49 ± 10

28.1 ± 5

28.1 ± 5

5

Placebo

Durga et al. 2005 [49]

Netherlands

Paralell, R, PC, DB

men and postmenopausal women

M/F: 530

264

266

52

60 ± 5

60 ± 6

NR

NR

0.8

Placebo

Moat et al. 2006 (a) [50]

USA

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 59

30

29

6

61 ± 7

61 ± 7

28.5 ± 4.4

29.6 ± 4.1

0.4

Placebo

Moat et al. 2006 (b) [50]

USA

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 54

25

29

6

60 ± 7

61 ± 7

29.9 ± 4.4

29.6 ± 4.1

5

Placebo

Title et al. 2006 [31]

Canada

Crossover, R, PC, DB

type 2 diabetes

M/F: 19

19

19

2

54.5 ± 5.9

54.5 ± 5.9

NR

NR

10

Placebo

Moens et al. 2007 [51]

Belgium

Crossover, R, PC, DB

Acute Myocardial Infarction

M/F: 40

20

20

6

57 ± 11

56 ± 14

NR

NR

10

Placebo

Shirodaria et al. 2007 (a) [52]

United Kingdom

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 34

20

14

1

62.2 ± 6.95

64 ± 8.9

28.2 ± 3.7

26.9 ± 4.5

0.4

Placebo

Shirodaria et al. 2007 (b) [52]

United Kingdom

Paralell, R, PC, DB

Coronary Artery Disease

M/F: 36

22

14

1

63.3 ± 7.5

64 ± 8.9

28 ± 3.5

26.9 ± 4.5

5

Placebo

Woo et al. 2008 [53]

China

Paralell, R, PC, DB

Subjects with Subnormal Intake

M/F: 104

51

53

24

45 ± 8

45 ± 8

NR

NR

5

Placebo

Palomba et al. 2010 [54]

Italy

Paralell, R, PC, DB

Polycystic Ovary Syndrome

F: 50

25

25

24

26.9 ± 3.1

26.4 ± 2.8

27.9 ± 2.6

28.1 ± 3.1

5

control group

Hashemi et al. 2016 [55]

Iran

Paralell, R, PC, TB

Pre eclamptic patients

F: 79

40

39

8

31.2 ± 4.3

30.82 ± 4.08

24.63 ± 2.64

25.19 ± 2.53

5

control group